Pharmaceuticals & Life Sciences · Pharmacovigilance & Drug Safety
Signal Detection & Safety Surveillance
Trajectories describe the observable direction of human effort — not a prediction about specific roles, headcount, or individual careers.
What You Do Today
Analyze aggregate safety data to detect new safety signals — disproportionality analysis across FAERS/EudraVigilance, periodic safety review, and signal evaluation from clinical trial databases. Prepare DSURs, PSURs/PBRERs, and safety sections of regulatory filings.
AI Technologies
Roles Involved
How It Works
AI performs continuous disproportionality analysis across global safety databases, flagging statistical signals that warrant medical evaluation. NLP mines medical literature for emerging safety information. Real-world evidence from claims databases and EHRs supplements traditional spontaneous reporting for signal validation.
What Changes
Signal detection shifts from periodic review cycles to continuous automated monitoring. AI surfaces potential signals weeks or months earlier than traditional quarterly review processes.
What Stays the Same
Medical evaluation of statistical signals — determining whether a disproportionality signal represents a true safety concern or a reporting artifact — requires clinical judgment and deep knowledge of the product's pharmacology and patient population.
Cross-Industry Concepts
Evidence & Sources
- •CIOMS working group signal detection guidelines
- •EMA GVP Module IX signal management
Sources listed are directional references, not formal citations. Verify against primary sources before using in business cases or presentations.
Last reviewed: March 2026
What To Do Next
This section won't tell you what your numbers should be. It will show you how to find them yourself. Every instruction below produces a real, verifiable result in your organization. No benchmarks, no projections — just the steps to build your own evidence.
Establish Your Baseline
Know where you are before you move
Before adopting AI tools for signal detection & safety surveillance, document your current state in pharmacovigilance & drug safety.
Without a baseline, you can't tell whether AI actually improved signal detection & safety surveillance or just changed who does it.
Define Your Measures
What to track and how to calculate it
findings per audit cycle
How to calculate
Measure findings per audit cycle for signal detection & safety surveillance before and after AI adoption. Pull from your compliance monitoring platform.
Why it matters
This is the most direct indicator of whether AI is adding value to pharmacovigilance & drug safety.
time to remediate
How to calculate
Track time to remediate using the same methodology you use today. Don't change how you measure just because you changed how you work.
Why it matters
Speed without quality is just faster mistakes. Measure both together.
Start These Conversations
Who to talk to and what to ask
Chief Compliance Officer
“What's our plan for AI in pharmacovigilance & drug safety? Are we piloting, planning, or waiting?”
This tells you whether to experiment quietly or push for formal investment in signal detection & safety surveillance.
your compliance monitoring platform administrator or vendor
“What AI capabilities exist in our current compliance monitoring platform that we're not using? Most platforms are adding AI features faster than teams adopt them.”
The cheapest AI adoption is the features already included in your existing license.
a practitioner in pharmacovigilance & drug safety at another organization
“Have you deployed AI for signal detection & safety surveillance? What worked, what didn't, and what would you do differently?”
Peer experience is more useful than vendor demos. Find someone who has actually done this.
Check Your Prerequisites
Confirm readiness before you invest
Check items as you confirm them.